Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

In the kitchen of her South St. Paul home, Abigail Turner prepares the insulin she uses to manage her type 1 diabetes last February. Minnesota announced a final settlement Monday with the last of ...

A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe Biden on lowering prescription drug costs in posts online that suggest ...

(ABC 6 News) – On Monday, Attorney General Keith Ellison announced a settlement with Novo Nordisk that let’s Minnesotans buy its insulin products for $35 per month. For the next five years ...

ST. PAUL, Minn. — Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable ...

The cost of some insulin products has surged by more than 1,100% over the past 20 years, according to a 2020 report from Ellison's advisory task force on lowering pharmaceutical drug prices.

Ellison accused Novo Nordisk, Eli Lilly and Sanofi of inflating patients' out-of-pocket costs for insulin based on the wholesale acquisition cost, or list price, of the drug. The drugmakers were ...

Minnesotans prescribed insulin won’t pay more than $35 per month for it, after the conclusion of a lawsuit against three major drug manufacturers. Minnesota Attorney General Keith Ellison ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin, a lifesaving drug used to treat diabetes. Ellison says uninsured and underinsured ...

All Minnesotans, with or without insurance, can buy insulin products for $35 per month, Minnesota Attorney General Keith Ellison announced Monday. A settlement with drug-maker Novo Nordisk resolves ...

In addition to the publications reviewed, evidence was also found to support the use of insulin aspart in combination therapy and areas currently ‘off-label´ such as pregnancy and/or ...